Systemic sclerosis (scleroderma, SSc) is one of the most challenging rheumatic diseases, characterized by vasculopathy, dysregulation of the immune response, and progressive tissue fibrosis affecting the skin, lungs, heart, digestive tract, and kidneys [...].

Institute of Rheumatology Department of Rheumatology of the 1st Faculty of Medicine Charles University Na Slupi 4 128 00 Prague Czech Republic

Zobrazit více v PubMed

Denton C.P., Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–1699. doi: 10.1016/S0140-6736(17)30933-9. PubMed DOI

Papadimitriou T.I., van Caam A., van der Kraan P.M., Thurlings R.M. Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis. Biomedicines. 2022;10:316. doi: 10.3390/biomedicines10020316. PubMed DOI PMC

Cardoneanu A., Burlui A.M., Macovei L.A., Bratoiu I., Richter P., Rezus E. Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6? Biomedicines. 2022;10:318. doi: 10.3390/biomedicines10020318. PubMed DOI PMC

Szabo I., Muntean L., Crisan T., Rednic V., Sirbe C., Rednic S. Novel Concepts in Systemic Sclerosis Pathogenesis: Role for miRNAs. Biomedicines. 2021;9:1471. doi: 10.3390/biomedicines9101471. PubMed DOI PMC

Zaaroor Levy M., Rabinowicz N., Yamila Kohon M., Shalom A., Berl A., Hornik-Lurie T., Drucker L., Tartakover Matalon S., Levy Y. MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors. Biomedicines. 2022;10:629. doi: 10.3390/biomedicines10030629. PubMed DOI PMC

Storkanova H., Storkanova L., Navratilova A., Becvar V., Hulejova H., Oreska S., Hermankova B., Spiritovic M., Becvar R., Pavelka K., et al. Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines. 2021;9:650. doi: 10.3390/biomedicines9060650. PubMed DOI PMC

Bogl T., Mlynek F., Himmelsbach M., Sepp N., Buchberger W., Geroldinger-Simic M. Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis. Biomedicines. 2022;10:607. doi: 10.3390/biomedicines10030607. PubMed DOI PMC

Grasshoff H., Fourlakis K., Comduhr S., Riemekasten G. Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis. Biomedicines. 2022;10:2150. doi: 10.3390/biomedicines10092150. PubMed DOI PMC

Aragona C.O., Versace A.G., Ioppolo C., La Rosa D., Lauro R., Tringali M.C., Tomeo S., Ferlazzo G., Roberts W.N., Bitto A., et al. Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease. Biomedicines. 2022;10:504. doi: 10.3390/biomedicines10020504. PubMed DOI PMC

Nagy T., Toth N.M., Palmer E., Polivka L., Csoma B., Nagy A., Eszes N., Vincze K., Barczi E., Bohacs A., et al. Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry. Biomedicines. 2022;10:2129. doi: 10.3390/biomedicines10092129. PubMed DOI PMC

Nagy A., Palmer E., Polivka L., Eszes N., Vincze K., Barczi E., Bohacs A., Tarnoki A.D., Tarnoki D.L., Nagy G., et al. Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox. Biomedicines. 2022;10:434. doi: 10.3390/biomedicines10020434. PubMed DOI PMC

Rauch L., Hein R., Biedermann T., Eyerich K., Lauffer F. Bisphosphonates for the Treatment of Calcinosis Cutis-A Retrospective Single-Center Study. Biomedicines. 2021;9:1698. doi: 10.3390/biomedicines9111698. PubMed DOI PMC